Plasma p-tau212 as a biomarker of sporadic and Down Syndrome Alzheimer's

2 disease

1

3

10

- 4 Przemysław R. Kac*, MSc¹, Daniel Alcolea*, MD, PhD^{2,3}, Laia Montoliu-Gaya, PhD¹, Susana
- 5 Fernández, MD¹⁴, Juan Lantero Rodriguez, PhD¹, Lucía Maure, MD^{2,3,14}, Fernando
- 6 González-Ortiz, MD^{1,4}, Bessy Benejam, PhD^{2,14}, Michael Turton, PhD⁵, Isabel Barroeta, MD
- 7 PhD^{2,3,14},Peter Harrison, MA⁵, Laura Videla, PhD^{2,3,14},Nicholas J. Ashton, PhD^{1,6,7,8}, Alberto
- 8 Lleó, MD PhD^{2,3}, Henrik Zetterberg, MD, PhD^{1,4,9,10,11,12}, María Carmona-Iragui, MD PhD^{2,3,14},
- 9 Thomas K. Karikari, PhD^{1,13}, Juan Fortea#, MD PhD^{2,3,14} and Kaj Blennow#, MD, PhD^{1,4,15,16}
- 11 Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of
- 12 Gothenburg, Mölndal, Sweden,
- 13 ²Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de
- 14 Barcelona, Barcelona, Spain,
- 15 ³Center for Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain,
- ⁴Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden,
- 17 ⁵Bioventix Plc, Farnham, GU9 7SX, United Kingdom,
- ${\rm ^6Centre\ for\ Age-Related\ Medicine,\ Stavanger\ University\ Hospital,\ Stavanger,\ Norway,}$
- 19 TNIHR Biomedical Research Centre for Mental Health & Biomedical Research Unit for Dementia at South London & Maudsley NHS
- 20 Foundation, London, United Kingdom,
- 21 Bepartment of Old Age Psychiatry, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, London,
- 22 United Kingdom,
- 23 ⁹Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of
- 24 Wisconsin-Madison, Madison, WI, USA,
- 25 ¹⁰Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Hong Kong, China, ¹¹Department of Neurodegenerative
- Disease, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom,
- 27 ¹²UK Dementia Research Institute at UCL, London, United Kingdom,
- ¹³Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA,
- 29 ¹⁴Barcelona Down Medical Center, Fundació Catalana Síndrome de Down, Barcelona, Spain
- 30 ¹⁵Paris Brain Institute, ICM, Pitié-Salpêtrière Hospital, Sorbonne University, Paris, France
- 31 ¹⁶Neurodegenerative Disorder Research Center, Division of Life Sciences and Medicine, and Department of Neurology, Institute on
- 32 Aging and Brain Disorders, University of Science and Technology of China and First Affiliated Hospital of USTC, Hefei, P.R. China
- 33 *Przemysław R. Kac and Daniel Alcolea contributed equally as first authors
- 34 #Kaj Blennow and Juan Fortea contributed equally as senior authors

Abstract

Background

All individuals with Down Syndrome (DS) will develop full-blown Alzheimer's disease (AD) pathology by age 40, decades before the occurrence of sporadic late-onset AD. Understanding this strong biological relation between age and AD pathology risk in DS is important to accelerate diagnostics, disease monitoring, and treatment. Several genes encoded in chromosome 21 including dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) have been proven to contribute to the pathology. A recently validated plasma immunoassay to measure tau phosphorylation at threonine-212 (p-tau212) has very high diagnostic accuracy in detecting AD. P-tau212 is also very sensitive to DYRK1A phosphorylation and is increased in DSAD brain lysates. Here, we assessed the potential of this biomarker in DSAD and sporadic AD.

Methods

Using Simoa technology, we tested p-tau212 and p-tau181 (n=245 for plasma, n=114 matching cerebrospinal fluid (CSF) samples). We used AUC-ROC to examine diagnostic performance and the DeLong test to compare the AUC-ROC differences between methods. Spearman correlation is used to examine correlations. Fold changes relative to median levels were calculated for their respective asymptomatic groups. ANCOVA followed by Tukey post-hoc test was used to calculate differences across groups. LOESS was used to determine the temporality of plasma biomarker changes.

Results

We have confirmed that p-tau212 has extremely high accuracy in detecting AD-related changes in euploid controls. For the DS population, we observed a strong correlation between plasma and CSF p-tau212 (r=0.867; p<0.001). In prodromal DS (pDS) and dementia DS (dDS), we observed significantly elevated levels of p-tau212 in reference to

asymptomatic DS (aDS). The diagnostic accuracy to differentiate between aDS and dDS was

AUC=0.91 and AUC = 0.86 in discriminating between DS amyloid positive and amyloid

negative participants. Plasma p-tau212 started increasing approximately when people

became amyloid PET-positive.

Conclusions

We have confirmed that the levels of plasma p-tau212 are increased in the DS population

and sporadic AD cases including prodromal and MCI states. Plasma p-tau212 might have

utility for theragnostic, monitoring therapy efficacy, and as a target engagement biomarker in

clinical trials both in sporadic and DSAD.

Keywords

- 71 Alzheimer's disease; Down Syndrome; plasma biomarkers; p-tau212; DYRK1A; DABNI;
- 72 SPIN; Simoa; CSF biomarkers.

Introduction

A triplication of chromosome 21 causes Down syndrome (DS)(1). All individuals with DS develop full-blown Alzheimer's Disease (AD) pathology by age 40(2) and the lifetime risk of developing AD exceeds 90% in the seventh decade(3). The estimated age of onset of AD dementia in this population is 53.8 years, decades before the occurrence of late-onset AD in the general population(4). Understanding this strong DSAD relationship is important to accelerate diagnostics and treatment. This ultra-high risk is mainly due to the triplication of the amyloid precursor protein (APP), which leads to the overproduction of amyloid- β ($A\beta$) peptides, and increased $A\beta$ plaques formation(5). Although other genes encoded in chromosome 21 such as dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) and RCAN1 contribute to the pathology(6–9). DYRK1A is a dose-sensitive gene

that overexpression contributes to DS cognitive dysfunction(10). This protein phosphorylates different targets involved in AD development and progression for instance Glycogen synthase kinase-3β (GSK-3β)(11), Presenilin1(12), APP(6), and tau(13).

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

Diagnosing DSAD is challenging due to the association of DS with cognitive dysfunction(14,15). Recent advances allow us to recognize ante-mortem AD pathology using blood-based biomarkers(16-19). These reflect the disease almost as accurately as more expensive and less available CSF and imaging biomarkers(20). Several plasma p-tau biomarkers have been found to reflect both AB and tau pathology(21). Recently validated plasma p-tau212 has shown very high performance for detecting those pathologies and AD diagnosis(22). That phosphorylation site might also have the strongest biological correlation with AD pathology in DS since threonine-212 is a primary target for DYRK1A in tau protein(23). Intensified phosphorylation at thr-212 induces tau aggregation, reduces tau binding to microtubules, and increases cell toxicity in in-vitro studies (24). Levels of p-tau212 are highly elevated in reference to AD and control participants in human AD-DS brains(25). Additionally, a major tau phosphatase - Protein phosphatase 1A (PP1A) is not dephosphorylating p-tau212 derived from AD brains(26), suggesting that this epitope might be vulnerable to very subtle changes related to AD pathology. Knowing that direct biological association, we hypothesized that p-tau212 is an accurate tau species to reflect AD pathology in the DS population. To test this hypothesis, we used Single molecule array (Simoa) immunoassays to measure plasma and cerebrospinal fluid (CSF) p-tau212 concentrations in asymptomatic DS (aDS), prodromal DS (pDS), and dementia DS (dDS) individuals, as well as in sporadic AD patients both in Mild Cognitive impairment (MCI) and dementia states and we compare the results with a validated biomarker.

Methods

Study design and participants

We performed a cross-sectional cohort study of adults with DS, and euploid individuals along the Alzheimer's disease continuum in the Hospital of Sant Pau, Barcelona (Spain), Adults with DS in Barcelona were recruited from a population-based health plan designed to screen for AD dementia, which includes yearly neurological and neuropsychological assessments. Those subjects interested in research studies are included in the Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) cohort(14,15). We also recruited euploid controls and sporadic Alzheimer's disease patients from the Sant Pau Initiative on Neurodegeneration (SPIN cohort)(27).

Biomarker measurements

Amyloid-β peptides (Aβ40, Aβ42) analyses were performed on the LUMIPULSE G600II, and the cut-off for positivity was defined as in the previous publication(28). All other plasma and CSF biomarker assays were performed on the Simoa HD-X platform at the University of Gothenburg. P-tau212 and p-tau181 concentrations were measured using published and validated in-house assays(16,22). For p-tau181, the AT270 antibody (Invitrogen) was used as a capture antibody and was paired with n-terminal antibody for detection (Tau12; BioLegend). For p-tau212, a sheep monoclonal antibody was used for capture paired with Tau12 as the detector. Coefficients of variation for 3 different internal quality controls for plasma were 5.3-12% for within-plate variation and 6.4%-12% for between-plate variation. For CSF, these values were 10.8%-13.3% and 12.9%-15.5%, respectively.

Statistical Analysis:

We used AUC-ROC to examine diagnostic performance and the DeLong test to compare the AUC-ROC differences between methods. Spearman correlation is used to examine

correlations. Fold changes relative to median levels are calculated for their respective asymptomatic groups. Age-adjusted analysis of covariance (ANCOVA) followed by Tukey post-hoc test is used to calculate differences across groups. A First-degree locally estimated scatterplot smoothing curve (LOESS) is independently used in controls and adults with Down Syndrome to determine the temporality of plasma biomarker changes. For Down participants we set the mean age of symptoms onset at 53.8 years according to a previous study from our group(29). All significance tests were two-sided, and significance was set at p<0.05.

Results

Cohort characteristics

We tested n=245 plasma samples for p-tau212 and p-tau181. A subset of participants had amyloid PET data. Table 1. shows the demographics, cognitive, and plasma biomarkers across groups of all participants included in the analyses. N=114 (47%) participants had CSF biomarker measurements. Demographics for the CSF subset are shown in Supplementary Table 1.

Correlations with biomarkers and cognition

Plasma and CSF p-tau212 were highly correlated with each other within the cohort. We observed moderate correlation across sample types in all participants (r=0.712 p<0.0001) (Fig. 1A). However, the strongest correlation of plasma p-tau212 with CSF p-tau212 was observed in the DS-only subgroup (r=0.867, p<0.0001) (Fig 1A). This improved CSF-plasma correlation in DS groups was not seen for p-tau181, which showed similar correlations in the whole cohort and subgroups (r=0.652-0.681, p<0.0001) (Fig 1B). Those results indicate that plasma p-tau212 measurements accurately reflect AD-related p-tau level changes in CSF in sporadic and DS groups.

Figure 1. Spearman correlations for plasma and CSF p-tau212 and p-tau181. The Figure shows correlations between plasma and CSF for **A)** p-tau212 and **B)** p-tau181 for euploid groups (n=88; p<0.001; r= 0.701 and r=0.660 respectively) and DS groups (n=26, p<0.001; r=0.867, r=0,681 respectively). The correlation between plasma and CSF measurements for all measurements (n=114, p<0.001) is 0.712 for p-tau212 and 0.652 for p-tau181. The fitted simple linear regression line is presented as a mean and error.

Both biomarkers were correlated with decrease in The Cambridge Cognitive Examination adapted for individuals with Down Syndrome (CAMCOG-DS) in plasma (r=-0.338; p=0.001 for p-tau212 and r=-0.328 for p-tau181; p=0.002;) and in CSF (r=-0.686; p<0.001 for p-tau212; and r=-0.511; p<0.001 for p-tau181).

Plasma p-tau212 levels are increased in asymptomatic Down syndrome

 Plasma p-tau212 concentration was 2.4x times higher in the aDS group compared with cognitively normal (CN) euploid people (p<0.001) whereas plasma p-tau181 was not significantly changed (p=0.052).

Plasma and CSF p-tau212 increase along the AD continuum in DSAD and sporadic AD Both in individuals with DS and euploid participants, p-tau212 levels were increased in symptomatic patients in comparison with asymptomatic individuals. (Fig. 2A). For pDS we observed a 3.4x (p=0.003) mean fold increase in plasma and a 5.6x mean fold-fold increase in CSF in reference to aDS. For dDS we observed a 2.9x (p=0.004) mean fold increase in plasma and a 7.1x mean fold increase in CSF. For MCI-AD, compared with cognitively normal euploid people, we observed a 3.0x (p<0.001) mean fold increase in plasma and a 7.8x mean fold increase in CSF. AD dementia patients had a 3.8x mean fold increase in plasma (p<0.001) and a 9.1x mean fold increase in CSF. P-tau181 concentrations were also increased, but with a lower magnitude than p-tau212, and comparison between DS groups showed no significance (Fig. 2B). Both biomarkers kept the pattern of greater increases in CSF than in plasma (Supplementary Fig. 1A-B).

Figure 2. Plasma p-tau212 and p-tau181 levels in euploid and Down Syndrome (DS) groups. Box plots represent median and IQR, and boundaries of the whiskers are minimum to maximum values for A) plasma p-tau212 and B) plasma p-tau181. Differences for euploid

participants are calculated for Mild Cognitively impaired Alzheimer's Disease (MCI-AD; n=62) and Alzheimer's Disease Dementia (AD; n=20) in reference to Cognitively Normal (CN; n=46) participants. Differences for prodromal Alzheimer's Disease in DS (pDS; n=8) and Alzheimer's Disease dementia in DS (dDS; n=17) are calculated in reference to asymptomatic (aDS; n=92). Age-adjusted analysis of covariance (ANCOVA) followed by Tukey post-hoc test is used to calculate differences across groups.

Plasma p-tau212 has greater diagnostic accuracy than p-tau181

ROC analysis was used to evaluate the diagnostic performance of plasma and CSF p-tau212 and p-tau181. AUCs were usually higher for biomarkers in CSF, and for p-tau212 than for p-tau181. In our comparisons, we included Age+ Apolipoprotein E4 (APOE4)+Sex since they have been shown to influence diagnostic accuracy(30). AUCs of Age+APOE+Sex were not significantly different from p-tau212 but better than p-tau181. Both biomarkers had high accuracy to differentiate between CN and AD in plasma AUC = 0.96 (95% CI 0.92-1) for p-tau212 and AUC = 0.89 (95% CI 0.84-0.95) for p-tau181 (Fig. 3B). For differentiating between CN and MCI-AD (Fig. 3A) or MCI-AD+AD (Fig. 3C), p-tau212 had accuracy of 0.91 (95% CI 0.85-0.97) and AUC=0.93 [95% CI 0.88-0.97] respectively. That accuracy was significantly higher than p-tau181 - (p=0.026 for both comparisons). Plasma p-tau212 reached AUC=0.91 (95% CI 0.86-0.97) to differentiate between aDS and dDS diagnosis (Fig. 3D).

Figure 3. Diagnostic accuracy of plasma and CSF biomarkers to discriminate between sporadic and DSAD groups. P-tau212 and p-tau181 receiver operating characteristic curves (ROC) to discriminate between sporadic and DSAD groups. Plasma p-tau181, plasma p-tau212, CSF p-tau181, CSF p-tau212, and Age+APOE+Sex are on each graph. In A) ROC curves for differentiating Cognitively normal (CN) and Mild Cognitive Impairment - Alzheimer's Dementia (MCI-AD). B) ROC curves to discriminate between CN and Alzheimer's Disease (AD). C) ROC curves to differentiate between CN and MCI-AD combined with AD group. D) ROC curves to discriminate between asymptomatic Down syndrome (aDS) and prodromal Down Syndrome (pDS) + dementia Down syndrome (dDS).

Plasma p-tau212 increases approximately parallel to amyloid PET positivity and has

great accuracy in discriminating between Aβ+ and Aβ- participants

231

232

233

234235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

Both biomarkers had significant accuracy in discriminating between Aβ+ and Aβ- participants (Fig. 4). Plasma p-tau212 had numerically higher accuracy than p-tau181 both for DS (AUC = 0.86 (95%CI = 0.7-1) (Fig. 4B) and euploid participants AUC = 0.9 (0.83 – 0.96) (Fig. 4C). Figure 4. Diagnostic accuracy of plasma and CSF biomarkers to discriminate between **Aβ+** and **Aβ-** participants. P-tau212 and p-tau181 receiver operating characteristic curves (ROC) to discriminate between amyloid positive (Aβ+) and amyloid negative (Aβ-) participants in sporadic and DSAD groups. Plasma p-tau181, plasma p-tau212, CSF ptau181, CSF p-tau212, and Age+APOE+Sex are on each graph. In A) ROC curves for differentiating A\(\beta+\) from A\(\beta-\) in whole cohort. **B**) ROC curves to discriminate A\(\beta+\) and A\(\beta-\) in DS groups. **C**) ROC curves to differentiate between Aβ+ and Aβ- in euploid groups. An early increase in plasma levels was observed many years before the onset of clinical AD symptoms in DS (Fig 5). For p-tau212 the increase started approximately when people became amyloid PET-positive, i.e., in their late 30s, and approximately 15 years before the disease onset (Fig. 5A). P-tau181 started increasing approximately 10 years before the estimated disease onset (Fig. 5B). Figure 5. Age-related plasma p-tau212 and p-tau181 changes in Down syndrome and euploid controls. Open Circles represent asymptomatic and filled circles represent symptomatic participants. Down syndrome population is represented in red and cognitively normal euploid people are represented in blue. Horizontal lines depict each group's fitted loess model, and fainted bands display confidence intervals. The vertical red line represents the estimated years to symptom onset which is 53.8 for Down syndrome participants and was used as reference in euploid controls for comparison purposes. Discussion In this cross-sectional study, we show that p-tau212 serves as a biomarker to track ADrelated changes in sporadic cases and DSAD. P-tau212 has a very high correlation between plasma and CSF. The strongest correlation was observed for the DS population, where ptau212 reached a greater correlation than for euploid participants. For p-tau181 correlation in euploid and DS groups was similar, suggesting greater translation from CSF to plasma for ptau212 in DS populations.

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

We observed elevated p-tau212 concentration in plasma and CSF in aDS compared with euploid CN. That elevation is greater than the p-tau181 elevation, which did not reach statistical significance. Additionally, other reported biomarkers, such as p-tau217 Glial fibrillary acidic protein (GFAP)(30,31), had lower increases. This suggests the effects of DYRK1A gene dose interacting with AD pathology on p-tau212 levels in DS and a better fit for the use of this biomarker in the DS population. Levels of plasma p-tau212 were significantly higher across disease groups. Plasma p-tau212 reached significance levels to differentiate between aDS vs pDS and aDS vs dDS groups while p-tau181 failed to do it. However, we think this might be a limitation of the small sample size used in this cohort since p-tau181 levels were previously shown to be significantly increased in pDS and aDS(30,32). In MCI-AD and AD dementia groups, we observed significant increases for both biomarkers, concomitantly having fold changes higher for ptau212 which confirms our previous findings(22). The excellent performance of the assay was confirmed in discriminating patients according to the diagnosis in both DS and euploid groups. P-tau212 additionally has greater accuracy than p-tau181 in discriminating between MCI-AD and control groups, simultaneously reaching 0.96 AUC to differentiate CN from AD. Additionally, plasma p-tau212 acquired very high AUC-ROC in discriminating between A\(\beta\)+ and A\(\beta\)- participants in both euploid and DS groups. This accuracy was not different from CSF accuracy, supporting the high betweenmatrix translation of p-tau212 and providing additional reasoning to use plasma p-tau212 to recruit participants for clinical trials. Plasma p-tau212 starts increasing in the 30s, approximately when people start being positive in amyloid PET scans, and 5 years before we observe an increase in p-tau181. Additionally, the biomarker increased further as AD progressed towards symptomatic stages. Therefore ptau212 could be useful to monitor the progression of asymptomatic DS people to prodromal AD. Moreover, the onset of the increase comes along with the appearance of neurofibrillary tangles (NFTs) and A β plaques in brain(4,33).

This is (to our best knowledge) the first study to measure p-tau212 in CSF and plasma as a biomarker for DSAD however, the potential involvement of p-tau212 in this population and its association with DYRK1A was published more than 20 years ago(13). The kinase is perceived as a target in DS and neurodegenerative diseases(8,34). Its under- or overexpression leads to different clinical phenotypes including cognitive impairment(34). Since DYRK1A is a dose-sensitive protein in which down-regulation or up-regulation has a critical role, DYRK1A inhibitors have already been widely explored in clinical trials and have been proven to improve cognitive function in DS people(10,35,36). Importantly, p-tau212 has already been successfully used to test the efficacy of DYRK1A inhibitor in cell models(37). The use of the chosen inhibitor was further shown to reverse the upregulation of p-tau212 in hippocampal tissue and temporal cortex in mouse models(37). Our novel plasma p-tau212 immunoassay provides a simple-to-implement and cost-effective opportunity to monitor the efficacy of DYRK1A inhibitors, or in the future – enhancers, not allowing the activity of this kinase to be reduced or increased to levels that could cause more harm than good. This utility will be explored in our future research.

The major strength of this study is the confirmation that p-tau212 is increased in the DS population, and levels of this biomarker increase with progression to AD dementia. P-tau212 reaches very high accuracy to differentiate between control and disease groups and Aβ+ and Aβ- participants. The high correlation between plasma and CSF p-tau212 also supports a very high translation of the results from CSF to plasma. DeLong tests between DS groups did not show any significantly better performance of CSF p-tau212 compared with plasma p-tau212 providing further evidence that plasma measurements can be used for clinical evaluation of AD pathophysiological processes occurring in patients with suspected disease. Advantages would also be reflected in the economy, availability, and perception of the test,

since lumbar punctures or PET scans are costly, require resources, and might be perceived as frightening(20). Next, plasma p-tau212 increased approximately when people are starting to be amyloid PET positive and 5 years before p-tau181, indicating the benefits in disease monitoring.

This study has a few limitations. First is a slightly low representation of prodromal-DS participants, which prohibits us from making better AUC-ROC analysis in that group. Ideally, longitudinal measurements of p-tau212 in the DS population would tell us more about the trajectories of this biomarker. The second limitation is that p-tau217 measurements are unavailable at the moment, however direct comparison between biomarkers was not a purpose of experiments presented in this article. Still, p-tau181 is the most commercialized and fully automated immunoassay, with great utility in AD.

Conclusions

In conclusion, we have confirmed that levels of plasma p-tau212 are increased in the DS population and sporadic AD cases including prodromal and MCI states. High accuracy in discriminating amyloid positive from amyloid negative people and increase in parallel to amyloid-PET positivity give the promise to evaluate ongoing pathophysiological AD processes many years before the disease onset in individuals with DS. This will also facilitate participants recrutation for clinical trials. This is a cost-effective application that provides higher chance to receive appropriate therapy. Plasma p-tau212 will also find high utility for theragnostic, to monitor therapy efficacy, and as a target engagement biomarker in clinical trials both in sporadic and DSAD.

Abbreviations

AD: Alzheimer's disease

347	DS: Down Syndrome
348	DYRK1A: dual-specificity tyrosine phosphorylation-regulated kinase 1A
349	p-tauX: tau phosphorylated at amino acid X
350	DSAD Down Syndrome Alzheimer's disease
351	CSF Cerebrospinal Fluid
352	AUC-ROC: Area Under the Curve and Receiver Operating Curves
353	ANCOVA: Age-adjusted analysis of covariance
354	LOESS: locally estimated scatterplot smoothing
355	pDS: prodromal Down syndrome
356	aDS: asymptomatic Down syndrome
357	dDS: dementia Down syndrome
358	PET: Positron Emission Tomography
359	MCI: mild cognitive impairment
360	Aβ: amyloid beta
361	APP: amyloid precursor protein
362	GSK-3β: Glycogen synthase kinase-3β
363	PP1A: Protein phosphatase 1A
364	DABNI: Down Alzheimer Barcelona Neuroimaging Initiative
365	SPIN: Sant Pau Initiative on Neurodegeneration

366 CN: cognitively normal 367 IQR; interquartile range 368 SD: standard deviation 369 CAMCOG-DS: The Cambridge Cognitive Examination adapted for individuals with Down 370 Syndrome 371 APOE4: Apolipoprotein E4 372 GFAP: Glial fibrillary acidic protein 373 NFTs: Neurofibrillary tangles 374 375 **Declarations** 376 Ethics approval and consent to participate 377 Study procedures were approved by the Sant Pau Ethics Committee (IIBSP-NGF-2018-36 378 and IIBSP-DOW-2014-30), following the standards for medical research in humans, as 379 recommended in the Declaration of Helsinki. All participants or their legally authorized 380 representative gave written informed consent before enrolment. 381 382 **Consent for publication** 383 Not applicable 384 385 Availability of data and materials 386 Blinded Anonymized data is available on reasonable request from the corresponding author. 387 Request will be reviewed by the investigators and respective institutions to verify if data 388 transfer is in the agreement with EU legislation on the general data protection or is subject to 389 any intellectual property or confidentiality obligations.

Competing interests

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

MT and PH are employees of Bioventix Plc. HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). KB has served as a consultant or at advisory boards for Abcam, Axon, BioArctic, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Ono Pharma, Pharmatrophix, Prothena, Roche Diagnostics, and Siemens Healthineers. HZ and KB are co-founders of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. D.A. participated in advisory boards from Fujirebio-Europe, Roche Diagnostics, Grifols S.A. and Lilly, and received speaker honoraria from Fujirebio-Europe, Roche Diagnostics, Nutricia, Krka Farmacéutica S.L., Zambon S.A.U. and Esteve Pharmaceuticals S.A. D.A. and JF declare a filed patent application (licensed to Adx, EPI8382175 J.F. reported receiving personal fees for service on the advisory boards, adjudication committees or speaker honoraria from AC Immune, Adamed, Alzheon, Biogen, Eisai, Esteve, Eisai, Fujirebio, Ionis, Laboratorios Carnot, Lilly, Life Molecular Imaging, Lundbeck, Perha, Roche, and, outside the submitted work. The other authors declare no competing interest.

Funding

- 415 PRK was funded by Demensförbundet and Anna Lisa and Brother Björnsson's Foundation.
- 416 LMG is supported by the Brightfocus Foundation (A2022015F), the Swedish Dementia

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

Foundation, Gun and Bertil Stohnes Foundation, Ahlén-stifelsen, Alzheimerfonden (AF-968621) and Gamla Tjänarinnor Foundation. FG-O was funded by the Anna Lisa and Brother Björnsson's Foundation. HZ is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397), the European Union's Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the Bluefield Project, Cure Alzheimer's Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familien Rönströms Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). KB is supported by the Swedish Research Council (#2017-00915 and #2022-00732), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721, #AF-968270, and #AF-994551), Hjärnfonden, Sweden (#FO2017-0243 and #ALZ2022-0006), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986 and #ALFGBG-965240), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the Alzheimer's Association 2021 Zenith Award (ZEN-21-848495), the Alzheimer's Association 2022-2025 Grant (SG-23-1038904 QC), La Fondation Recherche Alzheimer (FRA), Paris, France, the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark, and Familien Rönströms Stiftelse, Stockholm, Sweden. TKK was supported by the NIH (R01 AG083874, RF1 AG052525-01, P30 AG066468-04, R01 AG053952, R01 MH121619, R37 AG023651, RF1 AG025516-12A1, R01 AG073267, R01 MH108509, R01 AG075336, R01 AG072641, P01 AG025204), the Swedish Research Council (Vetenskåpradet; #2021-03244), the Alzheimer's Association (#AARF-21-850325), the Swedish Alzheimer Foundation (Alzheimerfonden), the Aina (Ann) Wallströms and Mary-Ann Sjöbloms stiftelsen, and the Emil och Wera Cornells stiftelsen. J.F was supported by the Fondo de Investigaciones Sanitario, Carlos III Health Institute (INT21/00073, Pl20/01473 and Pl23/01786) and the Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas Program 1, partly jointly funded by Fondo Europeo de Desarrollo Regional, Unión Europea, Una Manera de Hacer Europa. This work was also supported by the National Institutes of Health grants (R01 AG056850; R21 AG056974, R01 AG061566, R01 AG081394 and R61AG066543), the Department de Salut de la Generalitat de Catalunya, Pla Estratègic de Recerca i Innovació en Salut (SLT006/17/00119). It was also supported by Fundación Tatiana Pérez de Guzmán el Bueno (IIBSP-DOW-2020-151) and Horizon 2020–Research and Innovation Framework Programme from the European Union (H2020-SC1-BHC-2018-2020).

Authors' contributions

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

465

466

471

472

- PRK, DA, NJA, HZ, TKK, JF and KB created the concept and design. Data acquisition and
- analysis was performed by PRK, DA, LMG, JLR, NJA, JF. SF, LM, BB, MT, IB, PH, LV, AL,
- 462 MC-I contributed to the sample selection/and or interpretation of the data. PKK, DA, LMG,
- JLR, FG-O, HZ, TKK, JF and KB drafted the manuscript, and all authors revised. All authors
- read and approved the final manuscript.

Acknowledgements

- We thank all the participants with Down syndrome, their families, and their carers for their
- 468 support of, and dedication to this research. We also acknowledge Fundació Catalana
- 469 Síndrome de Down for global support and the members of the Alzheimer Down Unit and the
- 470 Memory Unit from Hospital de la Santa Creu i Sant Pau for their daily work and dedication.

References

- 1. Lejeune J, Gautier M, Turpin R. [Study of somatic chromosomes from 9 mongoloid
- children]. Comptes Rendus Hebd Seances Acad Sci. 1959 Mar 16;248(11):1721–2.
- 2. Wisniewski KE, Wisniewski HM, Wen GY. Occurrence of neuropathological changes and
- dementia of Alzheimer's disease in Down's syndrome. Ann Neurol. 1985;17(3):278–82.
- 477 3. McCarron M, McCallion P, Reilly E, Dunne P, Carroll R, Mulryan N. A prospective 20-
- 478 year longitudinal follow-up of dementia in persons with Down syndrome. J Intellect
- 479 Disabil Res. 2017;61(9):843–52.
- 480 4. Fortea J, Zaman SH, Hartley S, Rafii MS, Head E, Carmona-Iragui M. Down syndrome-
- 481 associated Alzheimer's disease: a genetic form of dementia. Lancet Neurol. 2021
- 482 Nov;20(11):930–42.
- 483 5. Ballard C, Mobley W, Hardy J, Williams G, Corbett A. Dementia in Down's syndrome.
- 484 Lancet Neurol. 2016 May 1;15(6):622-36.
- 485 6. Kimura R, Kamino K, Yamamoto M, Nuripa A, Kida T, Kazui H, et al. The DYRK1A gene,
- 486 encoded in chromosome 21 Down syndrome critical region, bridges between beta-
- 487 amyloid production and tau phosphorylation in Alzheimer disease. Hum Mol Genet. 2007
- 488 Jan 1;16(1):15–23.
- 489 7. Branca C, Shaw DM, Belfiore R, Gokhale V, Shaw AY, Foley C, et al. Dyrk1 inhibition
- improves Alzheimer's disease-like pathology. Aging Cell. 2017 Oct;16(5):1146–54.
- 491 8. Wegiel J, Kaczmarski W, Barua M, Kuchna I, Nowicki K, Wang KC, et al. Link between
- DYRK1A overexpression and several-fold enhancement of neurofibrillary degeneration
- 493 with 3-repeat tau protein in Down syndrome. J Neuropathol Exp Neurol. 2011
- 494 Jan;70(1):36–50.
- 495 9. Ermak G, Harris CD, Battocchio D, Davies KJA. RCAN1 (DSCR1 or Adapt78) stimulates
- 496 expression of GSK-3beta. FEBS J. 2006 May;273(10):2100–9.

497 10. Duchon A, Herault Y. DYRK1A, a Dosage-Sensitive Gene Involved in 498 Neurodevelopmental Disorders, Is a Target for Drug Development in Down Syndrome. 499 Front Behav Neurosci [Internet]. 2016 [cited 2021 Jul 14];10. Available from: 500 https://www.frontiersin.org/articles/10.3389/fnbeh.2016.00104/full#B228 501 11. Skurat AV, Dietrich AD. Phosphorylation of Ser640 in muscle glycogen synthase by 502 DYRK family protein kinases. J Biol Chem. 2004 Jan 23;279(4):2490-8. 503 12. Ryu YS, Park SY, Jung MS, Yoon SH, Kwen MY, Lee SY, et al. Dyrk1A-mediated 504 phosphorylation of Presenilin 1: a functional link between Down syndrome and 505 Alzheimer's disease. J Neurochem. 2010;115(3):574-84. 506 13. Woods YL, Cohen P, Becker W, Jakes R, Goedert M, Wang X, et al. The kinase DYRK 507 phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the 508 microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen 509 synthase kinase 3-priming kinase. Biochem J. 2001 May 1;355(Pt 3):609–15. 510 14. Fortea J. Carmona-Iraqui M. Benejam B. Fernández S. Videla L. Barroeta I. et al. Plasma 511 and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down 512 syndrome: a cross-sectional study. Lancet Neurol. 2018 Oct 1;17(10):860–9. 513 15. Fortea J, Vilaplana E, Carmona-Iragui M, Benejam B, Videla L, Barroeta I, et al. Clinical 514 and biomarker changes of Alzheimer's disease in adults with Down syndrome: a crosssectional study. The Lancet. 2020 Jun 27;395(10242):1988-97. 515 516 16. Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, et al. Blood 517 phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic 518 performance and prediction modelling study using data from four prospective cohorts.

Lancet Neurol. 2020 May;19(5):422-33.

519

- 17. Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, et al.
- 521 Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other
- Neurodegenerative Disorders. JAMA. 2020 Aug 25;324(8):772–81.
- 18. Ashton NJ, Pascoal TA, Karikari TK, Benedet AL, Lantero-Rodriguez J, Brinkmalm G, et
- al. Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology. Acta
- 525 Neuropathol (Berl). 2021 May 1;141(5):709–24.
- 19. Kac PR, Gonzalez-Ortiz F, Simrén J, Dewit N, Vanmechelen E, Zetterberg H, et al.
- 527 Diagnostic value of serum versus plasma phospho-tau for Alzheimer's disease.
- 528 Alzheimers Res Ther. 2022 May 11;14(1):65.
- 529 20. Gonzalez-Ortiz F, Kac PR, Brum WS, Zetterberg H, Blennow K, Karikari TK. Plasma
- 530 phospho-tau in Alzheimer's disease: towards diagnostic and therapeutic trial
- applications. Mol Neurodegener. 2023 Mar 16;18(1):18.
- 532 21. Mattsson-Carlgren N, Janelidze S, Bateman RJ, Smith R, Stomrud E, Serrano GE, et al.
- Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of
- amyloid with tau. EMBO Mol Med. 2021 Jun 8:13(6):e14022.
- 535 22. Kac PR, González-Ortiz F, Emeršič A, Dulewicz M, Koutarapu S, Turton M, et al. Plasma
- 536 p-tau212 antemortem diagnostic performance and prediction of autopsy verification of
- 537 Alzheimer's disease neuropathology. Nat Commun. 2024 Mar 23;15(1):2615.
- 23. Liu F, Liang Z, Wegiel J, Hwang YW, Igbal K, Grundke-Igbal I, et al. Overexpression of
- 539 Dyrk1A contributes to neurofibrillary degeneration in Down syndrome. FASEB J. 2008
- 540 Sep;22(9):3224–33.
- 24. Alonso AD, Di Clerico J, Li B, Corbo CP, Alaniz ME, Grundke-Iqbal I, et al.
- Phosphorylation of Tau at Thr212, Thr231, and Ser262 Combined Causes
- Neurodegeneration. J Biol Chem. 2010 Oct 1;285(40):30851–60.

544 25. Sawa M, Overk C, Becker A, Derse D, Albay R, Weldy K, et al. Impact of increased APP 545 gene dose in Down syndrome and the Dp16 mouse model. Alzheimers Dement. 546 2022;18(6):1203-34. 547 26. Rahman A, Grundke-Igbal I, Igbal K. Phosphothreonine-212 of Alzheimer abnormally 548 hyperphosphorylated tau is a preferred substrate of protein phosphatase-1. Neurochem 549 Res. 2005 Feb;30(2):277-87. 550 27. Alcolea D, Clarimón J, Carmona-Iraqui M, Illán-Gala I, Morenas-Rodríguez E, Barroeta I, 551 et al. The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for 552 biomarker discovery and validation in neurodegenerative disorders. Alzheimers Dement 553 N Y N. 2019;5:597–609. 554 28. Alcolea D, Pegueroles J, Muñoz L, Camacho V, López-Mora D, Fernández-León A, et al. 555 Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse. Ann Clin Transl Neurol. 2019 Sep;6(9):1815-24. 556 557 29. Iulita MF, Garzón Chavez D, Klitgaard Christensen M, Valle Tamayo N, Plana-Ripoll O, 558 Rasmussen SA, et al. Association of Alzheimer Disease With Life Expectancy in People 559 With Down Syndrome. JAMA Netw Open. 2022 May 23;5(5):e2212910. 560 30. Montoliu-Gaya L, Alcolea D, Ashton NJ, Pegueroles J, Levin J, Bosch B, et al. Plasma 561 and cerebrospinal fluid glial fibrillary acidic protein levels in adults with Down syndrome: 562 a longitudinal cohort study. eBioMedicine. 2023 Mar 30;90:104547. 563 31. Janelidze S, Christian BT, Price J, Laymon C, Schupf N, Klunk WE, et al. Detection of 564 Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers. JAMA Neurol. 2022

565

Aug 1;79(8):797–807.

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

32. Lleó A, Zetterberg H, Pegueroles J, Karikari TK, Carmona-Iragui M, Ashton NJ, et al. Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome. Nat Commun. 2021 Jul 14;12(1):4304. 33. Lott IT, Head E. Dementia in Down syndrome: unique insights for Alzheimer disease research. Nat Rev Neurol. 2019 Mar;15(3):135-47. 34. Deboever E, Fistrovich A, Hulme C, Dunckley T. The Omnipresence of DYRK1A in Human Diseases. Int J Mol Sci. 2022 Aug 19;23(16):9355. 35. Murphy AJ, Wilton SD, Aung-Htut MT, McIntosh CS. Down syndrome and DYRK1A overexpression: relationships and future therapeutic directions. Front Mol Neurosci. 2024 Jul 24;17:1391564. 36. De la Torre R, De Sola S, Pons M, Duchon A, de Lagran MM, Farré M, et al. Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans. Mol Nutr Food Res. 2014 Feb;58(2):278-88. 37. Chen H, Gao X, Li X, Yu C, Liu W, Qiu J, et al. Discovery of ZJCK-6-46: A Potent, Selective, and Orally Available Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor for the Treatment of Alzheimer's Disease. J Med Chem. 2024 Aug 8;67(15):12571–600.

A


P-tau212 Spearman correlation


r=0.7012 (95% CI 0.5722 - 0.7963) -- Euploid groups r=0.8674 (95% CI 0.7170 - 0.9406) - DS groups 3000 ¬ 2000-1000-0.0 0.5 1.0 2.0 2.5


Plasma p-tau212, pg/ml


P-tau181 Spearman Correlation

r=0.6602 (95% CI 0.5185 - 0.7666) - Euploid groups r=0.6807 (95% CI 0.3882 - 0.8486) - DS groups










medRxiv preprint doi: https://doi.org/10.1101/2024.109C243104W.Phpatiscipasts (Near Section 2, 2024. The copyright holder for this preprint (which was not certified by geer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 40 International license.






Table 1. Study Participants

	aDS	pDS	dDS	CN	MCI-AD	AD
n=	36/56	5/3	8/9	31/15	35/27	12/8
Female/Male	(39.1/60.9%)	(62.5/37.5%)	(47.1/52.9%)	(67.4/32.6%)	(56.5/43.5%)	(60/40%)
AGE (years)-range	18-62	41-60	46-59	18-75	56-83	53-83
AGE (years)-mean(sd)	42.2 (9.78)	51.5 (7.41)	51.8 (3.75)	50 (14.8)	72.3 (6.03)	70.5 (8.94)
AGE (years)-median[IQR]	44 [35.8-49]	52 [46.2-57]	52 [49-55]	46.5 [39-63.8]	72 [68-76.8]	71 [64.8-77.5]
	68/23	7/1	13/4	39/7	24/37	10/10
APOE4-/APOE4+	(74.7/25.3%)	(87.5/12.5%)	(76.5/23.5%)	(84.8/15.2%)	(39.3/60.7%)	(50/50%)
Plasma p-tau212 n	92	8	17	46	62	20
Plasma p-tau212 range	0.0435-1.69	0.666-2	0.404-2	0.0163-0.444	0.079-1.65	0.174-1.23
Plasma p-tau212 mean						
(SD)	0.404 (0.377)	1.11 (0.445)	0.929 (0.46)	0.166 (0.0856)	0.498 (0.28)	0.629 (0.29)
Plasma p-tau212	0.245	0.926 [0.831-	0.764	0.151	0.427	0.65
median[IQR]	[0.156-0.529]	1.24]	[0.627-1.23]	[0.113-0.235]	[0.33-0.632]	[0.372-0.738]
Plasma p-tau181 range	3.34-47.8	17-50.1	13.5-42.9	3.95-41.6	4.97-53.7	11.4-37.8
Plasma p-tau181 mean						
(SD)	15.9 (10.9)	29 (11.8)	23.5 (8.18)	11.1 (7.03)	22.3 (11.5)	22.6 (7.01)
Plasma p-tau181	11.7	24.7	21.6	9.02	19.3	22.5
median[IQR]	[7.54-20.9]	[20.4-35.3]	[18.9-27.7]	[7.07-12.7]	[14.6-27.9]	[18.2-27.4]
Total CAMCOG-DS score-						
n	73	3	12	0	0	0
Total CAMCOG-DS score-						
range	25-102	6-56	32-77	-	-	-
Total CAMCOG-DS score-						
mean(sd)	70.7 (20)	37.7 (27.5)	49.8 (13)	-	-	-
Total CAMCOG-DS score-						
median[IQR]	74 [57-87]	51 [28.5-53.5]	52 [38.5-57.2]	-		-

aDS – asymptomatic Down syndrome; pDS – prodromal Down syndrome; dDS – dementia Down syndrome; CN – cognitively normal; MCI-AD – mild cognitive impairment due to Alzheimer's Disease; AD – Alzheimer's disease dementia; IQR – interquartile range; SD – standard deviation. CAMCOG-DS The Cambridge Cognitive Examination adapted for individuals with Down Syndrome